{"protocolSection": {"identificationModule": {"nctId": "NCT01069510", "orgStudyIdInfo": {"id": "eIRB 5845"}, "secondaryIdInfos": [{"id": "K23HL093024-01A1", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/K23HL093024-01A1"}], "organization": {"fullName": "Oregon Health and Science University", "class": "OTHER"}, "briefTitle": "Spironolactone in Adult Congenital Heart Disease", "officialTitle": "Heart Failure in Congenital Heart Disease: the Role of Myocardial Fibrosis. Treatment Sub-Study: Spironolactone vs. Placebo"}, "statusModule": {"statusVerifiedDate": "2019-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-02"}, "primaryCompletionDateStruct": {"date": "2016-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-02-16", "studyFirstSubmitQcDate": "2010-02-16", "studyFirstPostDateStruct": {"date": "2010-02-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-07-30", "resultsFirstSubmitQcDate": "2019-07-30", "resultsFirstPostDateStruct": {"date": "2019-08-21", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-07-30", "lastUpdatePostDateStruct": {"date": "2019-08-21", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Craig Broberg", "investigatorTitle": "Associate Professor", "investigatorAffiliation": "Oregon Health and Science University"}, "leadSponsor": {"name": "Oregon Health and Science University", "class": "OTHER"}, "collaborators": [{"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}, {"name": "Oregon Clinical and Translational Research Institute", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to see if the study drug called spironolactone reduces fibrous (stiffening) in heart muscle tissue and improves heart function. Subjects from the study titled \"Heart Failure in Congenital Heart Disease: the role of myocardial fibrosis\" who have evidence of heart dysfunction and/or evidence of fibrosis (stiffening) in the heart muscle will be asked to take part in this study.", "detailedDescription": "This study will include randomizing the subject to receive the study drug or placebo. Randomization will occur during visit 1.\n\nVisit 1 will include the following:\n\n* Subjects will answer questions about how well they can breathe.\n* An MRI. Dye called gadolinium will be injected into the subject's vein.\n* They will go to the Oregon Clinical and Translational Research Institute where 2 tablespoons of blood will be drawn from an intravenous (IV) catheter (tube).\n* They will do a 6 minute walk test..\n* They will also have an echocardiogram, which is a test that looks at the movement of the subject's heart. A technician will place a cool jelly on their chest and use a small wand to take pictures through the skin.\n\nSubjects' will also have visits 3-6 weeks, 3, 6, 9 months, and 12 months after randomization. Visits 2-5 will include the following:\n\n* They will go to the Oregon Clinical and Translational Research Institute where 1/2 tablespoon of blood will be drawn.\n* They will do a 6 minute walk test. During this test, they will walk back and forth in a hallway. The goal is to walk as far as possible for 6 minutes. Subjects will probably get out of breath or become exhausted. If they do, they can slow down, stop, or rest as they need to. Blood pressure will be taken before the walk.\n* They will have a health review at 6 months.\n\nVisit 6 will be identical to visit 1 and include the following:\n\n* Subjects will answer questions about how well they can breathe.\n* An MRI. Dye called gadolinium will be injected into the subject's vein.\n* They will go to the Oregon Clinical and Translational Research Institute where 2 tablespoons of blood will be drawn from an intravenous (IV) catheter (tube).\n* They will do a 6 minute walk test..\n* They will also have an echocardiogram, which is a test that looks at the movement of the subject's heart. A technician will place a cool jelly on their chest and use a small wand to take pictures through the skin.\n\nThe investigators will compare the study drug, called spironolactone, to placebo with regard to any changes in heart stiffening and function of the heart."}, "conditionsModule": {"conditions": ["Congenital Heart Disease", "Heart Failure", "Endomyocardial Fibrosis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 40, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Patients will receive placebo", "interventionNames": ["Other: Placebo"]}, {"label": "Spironolactone", "type": "EXPERIMENTAL", "description": "Spironolactone 25 mg daily", "interventionNames": ["Drug: Spironolactone 25mg"]}], "interventions": [{"type": "DRUG", "name": "Spironolactone 25mg", "description": "Spironolactone 25 mg daily for 12 months", "armGroupLabels": ["Spironolactone"], "otherNames": ["Aldactone 25 mg daily"]}, {"type": "OTHER", "name": "Placebo", "description": "Placebo daily for 12 months", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Extracellular Volume Fraction", "description": "extracellular volume fraction measured by T1 mapping with MRI", "timeFrame": "12 month"}], "secondaryOutcomes": [{"measure": "6-minute Walk Distance", "description": "distance walked recorded in meters after 6 minutes on flat ground", "timeFrame": "12 month"}, {"measure": "Procollagen 3 NT Peptide", "timeFrame": "12 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Fibrosis index \u226529%, or\n2. Evidence of cardiovascular dysfunction including any of the following:\n\n   * Systemic ejection fraction \\<55%,\n   * NYHA 2-3\n   * 6-minute walk distance \\<500 m.\n3. Completion of Visit 1 of the study Heart Failure in Congenital Heart Disease: the role of myocardial fibrosis\" (eIRB # 3665) including meeting all inclusion for that study (Aged 18-80, Known congenital heart disease).\n4. Tetralogy of Fallot, cyanotic congenital heart disease, or a systemic right ventricle.\n\nExclusion Criteria:\n\n1. Patient currently taking spironolactone or previously taking spironolactone within the last 6 months.\n2. Serum potassium \u22655.0 mmol/L at the initial visit, if not taking potassium supplements. Patients will be eligible if a repeat potassium is \\<5.0 mmol/L after potassium supplements have been discontinued.\n3. Moderate/severe systemic atrioventricular valve regurgitation,\n4. Likely to undergo cardiac surgery, pacemaker implantation, or possible transplantation within one year (all self-reported),\n5. Unwilling to commit to return visits including mandatory blood draws for potassium,\n6. Renal insufficiency (estimated creatinine clearance \\< 30 ml/min/1.73m2),\n7. Positive urine pregnancy test.\n8. Any contraindication to MRI.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Craig Broberg, MD", "affiliation": "Oregon Health and Science University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Oregon Health & Science University", "city": "Portland", "state": "Oregon", "zip": "97239", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Recruited at time of presentation for larger study. However, most did not meet enrollment criteria and could not be randomized.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Patients will receive placebo\n\nPlacebo: Placebo daily for 12 months"}, {"id": "FG001", "title": "Spironolactone", "description": "Spironolactone 25 mg daily\n\nSpironolactone 25mg: Spironolactone 25 mg daily for 12 months"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Patients will receive placebo\n\nPlacebo: Placebo daily for 12 months"}, {"id": "BG001", "title": "Spironolactone", "description": "Spironolactone 25 mg daily\n\nSpironolactone 25mg: Spironolactone 25 mg daily for 12 months"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "15"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "36", "spread": "6"}, {"groupId": "BG001", "value": "38", "spread": "16"}, {"groupId": "BG002", "value": "37", "spread": "11"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "9"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "15"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Extracellular Volume Fraction", "description": "extracellular volume fraction measured by T1 mapping with MRI", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of myocardium", "timeFrame": "12 month", "groups": [{"id": "OG000", "title": "Placebo", "description": "Patients will receive placebo\n\nPlacebo: Placebo daily for 12 months"}, {"id": "OG001", "title": "Spironolactone", "description": "Spironolactone 25 mg daily\n\nSpironolactone 25mg: Spironolactone 25 mg daily for 12 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "7"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "30.1", "spread": "3.8"}, {"groupId": "OG001", "value": "25.3", "spread": "1.5"}]}]}]}, {"type": "SECONDARY", "title": "6-minute Walk Distance", "description": "distance walked recorded in meters after 6 minutes on flat ground", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "meters", "timeFrame": "12 month", "groups": [{"id": "OG000", "title": "Placebo", "description": "Patients will receive placebo\n\nPlacebo: Placebo daily for 12 months"}, {"id": "OG001", "title": "Spironolactone", "description": "Spironolactone 25 mg daily\n\nSpironolactone 25mg: Spironolactone 25 mg daily for 12 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "7"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "516", "spread": "124"}, {"groupId": "OG001", "value": "492", "spread": "138"}]}]}]}, {"type": "SECONDARY", "title": "Procollagen 3 NT Peptide", "populationDescription": "Limited samples obtained from participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mcg/l", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "Placebo", "description": "Patients will receive placebo\n\nPlacebo: Placebo daily for 12 months"}, {"id": "OG001", "title": "Spironolactone", "description": "Spironolactone 25 mg daily\n\nSpironolactone 25mg: Spironolactone 25 mg daily for 12 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3", "spread": ".7"}, {"groupId": "OG001", "value": "4.8", "spread": "1.2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Patients will receive placebo\n\nPlacebo: Placebo daily for 12 months", "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 0, "otherNumAtRisk": 8}, {"id": "EG001", "title": "Spironolactone", "description": "Spironolactone 25 mg daily\n\nSpironolactone 25mg: Spironolactone 25 mg daily for 12 months", "seriousNumAffected": 0, "seriousNumAtRisk": 7, "otherNumAffected": 0, "otherNumAtRisk": 7}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Craig Broberg", "organization": "Oregon Health and Science Univ.", "email": "brobergc@ohsu.edu", "phone": "503-494-7400"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000006330", "term": "Heart Defects, Congenital"}, {"id": "D000004719", "term": "Endomyocardial Fibrosis"}, {"id": "D000005355", "term": "Fibrosis"}], "ancestors": [{"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000010335", "term": "Pathologic Processes"}, {"id": "D000018376", "term": "Cardiovascular Abnormalities"}, {"id": "D000000013", "term": "Congenital Abnormalities"}, {"id": "D000009202", "term": "Cardiomyopathies"}], "browseLeaves": [{"id": "M9419", "name": "Heart Diseases", "asFound": "Heart Disease", "relevance": "HIGH"}, {"id": "M9418", "name": "Heart Defects, Congenital", "asFound": "Congenital Heart Disease", "relevance": "HIGH"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M8485", "name": "Fibrosis", "asFound": "Fibrosis", "relevance": "HIGH"}, {"id": "M7881", "name": "Endomyocardial Fibrosis", "asFound": "Endomyocardial Fibrosis", "relevance": "HIGH"}, {"id": "M12", "name": "Congenital Abnormalities", "relevance": "LOW"}, {"id": "M20503", "name": "Cardiovascular Abnormalities", "relevance": "LOW"}, {"id": "M12154", "name": "Cardiomyopathies", "relevance": "LOW"}, {"id": "T2074", "name": "Endomyocardial Fibrosis", "asFound": "Endomyocardial Fibrosis", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC16", "name": "Diseases and Abnormalities at or Before Birth"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000013148", "term": "Spironolactone"}], "ancestors": [{"id": "D000000451", "term": "Mineralocorticoid Receptor Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000062865", "term": "Diuretics, Potassium Sparing"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}], "browseLeaves": [{"id": "M15943", "name": "Spironolactone", "asFound": "Estradiol", "relevance": "HIGH"}, {"id": "M3797", "name": "Mineralocorticoid Receptor Antagonists", "relevance": "LOW"}, {"id": "M11871", "name": "Mineralocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M30025", "name": "Diuretics, Potassium Sparing", "relevance": "LOW"}], "browseBranches": [{"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}